富祥药业x药融圈达成战略合作，共筑生物制造新质生产力

Group 1 - Jiangxi Fuxiang Pharmaceutical Co., Ltd. (stock code: 300497) has officially signed a strategic cooperation agreement with the pharmaceutical information and networking platform Yaorongquan, aiming for deep integration in the pharmaceutical and biomanufacturing sectors to promote technological innovation and industrialization [1][13] - The cooperation will focus on Fuxiang's three major industry segments: pharmaceuticals, new energy materials, and biomanufacturing, enhancing collaboration in product development, visual systems, key projects, and talent recommendations [8][20] - Fuxiang has established itself as a significant player in the biomanufacturing field, with its subsidiary Fuxiang Biotechnology being the first in China to achieve ton-level industrialization of new protein, with an annual production line capacity of 1,200 tons [2][15] Group 2 - Fuxiang Pharmaceutical has received approval from the National Health Commission, marking a milestone in its biomanufacturing development and positively impacting domestic food manufacturing and national food security [6][18] - The company operates in three main sectors: pharmaceuticals, new energy materials, and biomanufacturing, with a strong focus on antibiotic raw materials and lithium battery electrolyte additives [9][22] - In the biomanufacturing sector, Fuxiang is recognized as Asia's first company to achieve ton-level industrialization of filamentous fungal protein and has developed a new production strain with independent intellectual property rights, currently holding a national invention patent [10][23]